Federal Register of Legislation - Australian Government

Primary content

PB 70 of 2020 Determinations/Health as made
This instrument amends the National Health (Continued Dispensing – Emergency Measures) Determination 2020 to provide for the addition of forms of the listed drugs metformin and salbutamol to the list of pharmaceutical benefits that can be supplied as a Continued Dispensing supply.
Administered by: Health
Registered 31 Jul 2020
Table of contents.

Commonwealth Coat of Arms of Australia

 

PB 70 of 2020

 

National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2020 (No. 6)

Dated               30 july             2020

 

           

Nikolai Tsyganov

Assistant Secretary (Acting)

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

 

 

 

 

 

 

 

                                           

                                           


 

 

 

 

 

Contents

1...... Name

2...... Commencement............................................................................................................................... 1

3...... Authority......................................................................................................................................... 1

4 ..... Schedule.......................................................................................................................................... 1

Schedule 1—Amendments                                                                                                                          2

National Health (Continued Dispensing - Emergency Measures) Determination 2020         2

 

 

 


1  Name

(1) This instrument is the National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2020 (No.6).

(2) This instrument may also be cited as PB 70 of 2020.

2  Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1.  The whole of this instrument

1 August 2020.

 

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

             (2)  Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

                   This instrument is made under subsection 89A(3) of the National Health Act 1953.

4  Schedules

                   Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.


Schedule 1Amendments

National Health (Continued Dispensing – Emergency Measures) Determination 2020

 

[1]        Schedule 1, after entry for Entacapone

insert:

Entrectinib

Capsule 200 mg

Oral

[2]        Schedule 1, after entry for Loperamide

insert:

Lorlatinib

Tablet 25 mg

Oral

 

Tablet 100 mg

Oral

[3]        Schedule 1, entry for Metformin

substitute:

Metformin

Tablet containing metformin hydrochloride 500 mg

Oral

 

Tablet containing metformin hydrochloride 850 mg

Oral

 

Tablet containing metformin hydrochloride 1 g

Oral

 

Tablet (extended release) containing metformin hydrochloride 500 mg

Oral

 

Tablet (extended release) containing metformin hydrochloride 1 g

Oral

 

Tablet (prolonged release) containing metformin hydrochloride 500 mg

Oral

[4]        Schedule 1, entry for Salbutamol

substitute:

Salbutamol

Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 20

Inhalation

 

Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 30

Inhalation

 

Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 20

Inhalation

 

Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 30

Inhalation

 

Oral solution 2 mg (as sulfate) per 5 mL, 150 mL

Oral

 

Pressurised inhalation in breath actuated device 100 micrograms (as sulfate) per dose, 200 doses (CFC‑free formulation)

Inhalation by mouth

 

Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC‑free formulation)

Inhalation by mouth

 

Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation)

Inhalation by mouth

[5]        Schedule 1, after entry for Sterculia with frangula bark

insert:

Stiripentol

Capsule 250 mg

Oral

 

Capsule 500 mg

Oral

 

Powder for oral suspension 250 mg

Oral

 

Powder for oral suspension 500 mg

Oral